DDDavid A. DeGoey

David A. DeGoey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David A. DeGoey has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Edward Price

    Research and Development, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States

    3 shared publications
  • Eric A. Voight

    AbbVie, Inc., North Chicago, Illinois 60064, United States

    3 shared publications
  • Alexey Rivkin

    Research and Development, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States

    2 shared publications
  • Cecilia Van Handel

    Abbvie Incorporated, Global Pharmaceutical Research and Development, 1 North Waukegan Road, North Chicago, Illinois 60064, United States

    2 shared publications
  • Clarence J. Maring

    Research and Development, AbbVie Inc., North Chicago, Illinois 60064, United States

    2 shared publications
  • Dachun Liu

    Research and Development, AbbVie Inc., North Chicago, Illinois 60064, United States

    2 shared publications

Latest Publications

  • Explainable Machine Learning for ETR and Drug Chameleonicity

    by Edward Price, Matthieu Dagommer, Mattson Thieme, Richard Hong, J. Cory Kalvass, Stella Doktor, Alexey Rivkin, Yue-Ting Wang, Philip Cox, Abhishek Pandey, et al.

    Explainable machine learning that identifies molecular “hot spots” for chameleonicity can guide rapid chemical design for oral absorption of beyond-rule-of-five (bRo5) drugs. Traditional in silico methods rely on computationally intensive 3D physics-based modeling or classical descriptors that do not fully explain bRo5 drug behavior. To address this, we introduced the EPSA-to-TPSA ratio (ETR) as a high-throughput measure of polarity reduction, generating data for thousands of macrocycles, PROTACs, and other bRo5s. Using this data set, we developed an explainable deep learning model to predict EPSA and locate polarity-reducing “hot spots” that influence chameleonicity. This first-of-its-kind interpretable model in the bRo5 3D domain guides chemical modifications before synthesis, helping chemists optimize physicochemical properties and design complex bRo5 drugs with improved oral bioavailability. Model insights validated by molecular dynamics enable robust, high-throughput predictions of bRo5 chameleonic behavior, building on Lipinski descriptors to establish new frameworks for complex drug design.


  • Open Access

    Development of a sensitive high-throughput enzymatic assay capable of measuring sub-nanomolar inhibitors of SARS-CoV2 Mpro

    by Peter Kovar, Paul L Richardson, Alla Korepanova, Gustavo A Afanador, Vladimir Stojkovic, Tao Li, Michael R Schrimpf, Teresa I Ng, David A Degoey, Sujatha M Gopalakrishnan, et al.


  • Top Cited Papers

    Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape

    by Edward Price, Manuel Weinheimer, Alexey Rivkin, Gary Jenkins, Marjoleen Nijsen, Philip B. Cox, David DeGoey

    Developing orally bioavailable drugs demands an understanding of absorption in early drug development. Traditional methods and physicochemical properties optimize absorption for rule of five (Ro5) compounds; beyond rule of five (bRo5) drugs necessitate advanced tools like the experimental measure of exposed polarity (EPSA) and the AbbVie multiparametric score (AB-MPS). Analyzing AB-MPS and EPSA against ∼1000 compounds with human absorption data and ∼10,000 AbbVie tool compounds (∼1000 proteolysis targeting chimeras or PROTACs, ∼7000 Ro5s, and ∼2000 bRo5s) revealed new patterns of physicochemical trends. We introduced a high-throughput "polarity reduction" descriptor: ETR, the EPSA-to-topological polar surface area (TPSA) ratio, highlights unique bRo5 and PROTAC subsets for specialized drug design strategies for effective absorption. Our methods and guidelines refine drug design by providing innovative in vitro approaches, enhancing physicochemical property optimization, and enabling accurate predictions of intestinal absorption in the complex bRo5 domain.


  • Open Access

    Antiviral Drug Discovery for the Treatment of COVID-19 Infections

    by Teresa I. Ng, Ivan Correia, Jane Seagal, David A. DeGoey, Michael R. Schrimpf, David J. Hardee, Elizabeth L. Noey, Warren M. Kati

    The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus. COVID-19 vaccines have proven to be successful in protecting the vaccinated from infection, reducing the severity of disease, and deterring the transmission of infection. However, COVID-19 vaccination faces many challenges, such as the decline in vaccine-induced immunity over time, and the decrease in potency against some SARS-CoV-2 variants including the recently emerged Omicron variant, resulting in breakthrough infections. The challenges that COVID-19 vaccination is facing highlight the importance of the discovery of antivirals to serve as another means to tackle the pandemic. To date, neutralizing antibodies that block viral entry by targeting the viral spike protein make up the largest class of antivirals that has received US FDA emergency use authorization (EUA) for COVID-19 treatment. In addition to the spike protein, other key targets for the discovery of direct-acting antivirals include viral enzymes that are essential for SARS-CoV-2 replication, such as RNA-dependent RNA polymerase and proteases, as judged by US FDA approval for remdesivir, and EUA for Paxlovid (nirmatrelvir + ritonavir) for treating COVID-19 infections. This review presents an overview of the current status and future direction of antiviral drug discovery for treating SARS-CoV-2 infections, covering important antiviral targets such as the viral spike protein, non-structural protein (nsp) 3 papain-like protease, nsp5 main protease, and the nsp12/nsp7/nsp8 RNA-dependent RNA polymerase complex.


  • Open Access

    Implications of the Conformationally Flexible, Macrocyclic Structure of the First-Generation, Direct-Acting Anti-Viral Paritaprevir on Its Solid Form Complexity and Chameleonic Behavior

    by Ahmad Y. Sheikh, Alessandra Mattei, Rajni Miglani Bhardwaj, Richard S. Hong, Nathan S. Abraham, Gabriela Schneider-Rauber, Kenneth M. Engstrom, Moiz Diwan, Rodger F. Henry, Yi Gao, et al.

    Direct-acting antiviral regimens have transformed therapeutic management of hepatitis C across all prevalent genotypes. Most of the chemical matter in these regimens comprises molecules well outside the traditional drug development chemical space and presents significant challenges. Herein, the implications of high conformational flexibility and the presence of a 15-membered macrocyclic ring in paritaprevir are studied through a combination of advanced computational and experimental methods with focus on molecular chameleonicity and crystal form complexity. The ability of the molecule to toggle between high and low 3D polar surface area (PSA) conformations is underpinned by intramolecular hydrogen bonding (IMHB) interactions and intramolecular steric effects. Computational studies consequently show a very significant difference of over 75 Å2 in 3D PSA between polar and apolar environments and provide the structural basis for the perplexingly favorable passive permeability of the molecule. Crystal packing and protein binding resulting in strong intermolecular interactions disrupt these intramolecular interactions. Crystalline Form I benefits from strong intermolecular interactions, whereas the weaker intermolecular interactions in Form II are partially compensated by the energetic advantage of an IMHB. Like Form I, no IMHB is observed within the receptor-bound conformation; instead, an intermolecular H-bond contributes to the potency of the molecule. The choice of metastable Form II is derisked through strategies accounting for crystal surface and packing features to manage higher form specific solid-state chemical reactivity and specific processing requirements. Overall, the results show an unambiguous link between structural features and derived properties from crystallization to dissolution, permeation, and docking into the protein pocket.


  • Open Access

    Desymmetrization of pibrentasvir for efficient prodrug synthesis

    by Eric A. Voight, Stephen N. Greszler, John Hartung, Jianguo Ji, Russell C. Klix, John T. Randolph, Bhadra H. Shelat, Jan E. Waters, David A. DeGoey

    Horeau principle statistical amplification and solubility-driven selectivities allow C2-desymmetrization of pibrentasvir without typically required internal functionalization or steric proximity effects.


  • Global Analysis of Models for Predicting Human Absorption: QSAR, In Vitro, and Preclinical Models

    by Edward Price, J. Cory Kalvass, David DeGoey, Balakrishna Hosmane, Stella Doktor, Kelly Desino

    Models intended to predict intestinal absorption are an essential part of the drug development process. Although many models exist for capturing intestinal absorption, many questions still exist around the applicability of these models to drug types like “beyond rule of 5” (bRo5) and low absorption compounds. This presents a challenge as current models have not been rigorously tested to understand intestinal absorption. Here, we assembled a large, structurally diverse dataset of ∼1000 compounds with known in vitro, preclinical, and human permeability and/or absorption data. In silico (quantitative structure–activity relationship), in vitro (Caco-2), and in vivo (rat) models were statistically evaluated for predictive performance against this human intestinal absorption dataset. We expect this evaluation to serve as a resource for DMPK scientists and medicinal/computational chemists to increase their understanding of permeability and absorption model utility and applications for academia and industry.


  • Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530)

    by John T. Randolph, Eric A. Voight, Stephen N. Greszler, Brice E. Uno, James N. Newton, Kenneth M. Gleason, DeAnne Stolarik, Cecilia Van Handel, Daniel A. J. Bow, David A. DeGoey

    A research program to discover solubilizing prodrugs of HCV NS5A inhibitor pibrentasvir (PIB) identified phosphomethyl analog 2 and trimethyl-lock (TML) prodrug 9. The prodrug moiety is attached to a benzimidazole nitrogen via an oxymethyl linkage to allow for rapid and complete release of the drug for absorption following phosphate removal by intestinal alkaline phosphatase. These prodrugs have good hydrolytic stability properties and improved solubility compared to PIB, both in aqueous buffer (pH 7) and FESSIF (pH 5). TML prodrug 9 provided superior in vivo performance, delivering high plasma concentrations of PIB in mouse, dog and monkey PK studies. The improved dissolution properties of these phosphate prodrugs give them potential to simplify drug dosage forms for PIB-containing HCV therapy.


  • Synthesis and evaluation of 2′-dihalo ribonucleotide prodrugs with activity against hepatitis C virus

    by A. Chris Krueger, Hui-Ju Chen, John T. Randolph, Brian S. Brown, Geoff T. Halvorsen, Howard R. Heyman, Tongmei Li, Christopher C. Marvin, Jason P. Shanley, Eric A. Voight, et al.


  • Top Cited Papers

    Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection

    by David A. DeGoey, Hui-Ju Chen, Philip B. Cox, Michael D. Wendt

    Recently, there has been an increasing focus on the pursuit of targets considered to be less-druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncology and virology. However, conducting drug discovery campaigns in “beyond Rule of 5” (bRo5) chemical space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics. Retrospective analysis of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compounds and improve the efficiency of drug design for future projects. We present here highlights and case studies of lessons learned from discovery of bRo5 compounds. A simple multi-parametric scoring function (AB-MPS) was devised which correlated preclinical PK results with cLogD, number of rotatable bonds and number of aromatic rings.